Neuroleptic-Induced Parkinsonism Increases with Repeated Treatment in Monkeys

  • D. E. Casey
Conference paper
Part of the Psychopharmacology Series book series (PSYCHOPHARM, volume 3)


Neuroleptic-induced extrapyramidal symptoms (dystonia, parkinsonism, and akathisia) are frequent side effect problems in managing acute psychosis. The prevalence of these neurological syndromes varies widely from 2.2%–95% (Sovner and DiMascio 1978). This broad range is undoubtedly influenced by multiple variables, including patient characteristics (age, sex, previous extrapyramidal symptoms), drug parameters (dose, milligram-potency), and temporal aspects (early, intermediate, late) (Keepers et al. 1983; Casey and Keepers 1985; Keepers and Casey 1985). For example, low-milligram high-potency neuroleptics produce more extrapyramidal symptoms than high-milligram low-potency drugs. Drug dosage is also a factor which correlates positively with symptom prevalence and severity. However, even when these factors are kept constant, some patients may develop symptoms while others do not. These differences are currently attributed to variations in individual vulnerability.


Tardive Dyskinesia Extrapyramidal Symptom Parkinsonian Syndrome Antiparkinson Drug Acute Psychosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ayd FJ (1961) A survey of drug-induced extrapyramidal reactions. JAMA 75: 1054–1060Google Scholar
  2. Casey de, Gerlach J, Christensson E (1980) Dopamine, acetylcholine, and GABA effects in acute dystonia in primates. Psychopharmacology (Berlin) 70: 83–87CrossRefGoogle Scholar
  3. Casey de, Clappison VJ, Keepers GA (1981) Anticholinergics in acute extrapyramidal symptoms. (abstract) Proc American Psychiatric Association 22d: 50Google Scholar
  4. Dimascio A, Demirgian E (1970) Antiparkinson drug overuse. Psychosomatics 11: 596–601PubMedGoogle Scholar
  5. Gunne LM, Barany S (1976) Haloperidol-induced tardive dyskinesia in monkeys. Psychopharmacology (Berlin) 50: 237–240CrossRefGoogle Scholar
  6. Keepers GA, Casey de (1985) Clinical management of acute neuroleptic-induced extrapyramidal syndromes. In: Masserman JH (ed) Current psychiatric therapies. Grune and Stratton, New YorkGoogle Scholar
  7. Keepers GA, Clappison VJ, Casey de (1983) Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch gen psychiatry 40: 1113–1117PubMedGoogle Scholar
  8. Klett CJ, Caffey E (1972) Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics. Arch Gen Psychiatry 26: 374–379PubMedGoogle Scholar
  9. Kovacic B, Domino EF (1984) Fluphenazine-induced acute and tardive dyskinesias in monkeys. Psychopharmacology (Berlin) 84: 310–314CrossRefGoogle Scholar
  10. Neale R, Gerhardt S, Fallon S, Liebman JM (1982) Progressive changes in the acute dyskinetic syndrome as a function of repeated elicitation in squirrel monkeys. Psychopharmacology (Berlin) 77: 223–228CrossRefGoogle Scholar
  11. Paulson GW (1973) Dyskinesias in monkeys. In: Chase TN, Paulson GW (eds) Advances in neurology, vol 1. Raven, New York, pp 647–650Google Scholar
  12. Porsolt R (1984) Lack of tolerance to haloperidol-induced acute dyskinesias in rhesus monkeys. Psychopharmacology (Berlin) 82: 145–146CrossRefGoogle Scholar
  13. Rifkin A, Quitkin F, Klein DF (1975) Akinesia: a poorly recognized drug-induced extrapyramidal behavioral disorder. Arch Gen Psychiatry 32: 672–674Google Scholar
  14. Simpson GM, Laska E (1968) Sensitivity to a phenothiazine (butaperazine). Can Psychiatr Assoc J 13: 499–505PubMedGoogle Scholar
  15. Sovner R, DiMascio A (1978) Extrapyramidal syndromes and other neurological side effects of psychotropic drugs. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven, New York, pp 1021–1032Google Scholar
  16. Weiss B, Santelli S, Lusink G (1977) Movement disorders induced in monkeys by chronic haloperidol treatment. Psychopharmacology (Berlin) 53: 289–293CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • D. E. Casey
    • 1
    • 2
    • 3
  1. 1.VA Medical CenterPortlandUSA
  2. 2.Oregon Health Sciences UniversityPortlandUSA
  3. 3.Oregon Regional Primate Research CenterPortlandUSA

Personalised recommendations